Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
By M. Sasako, S. Sakuramoto, H. Katai, T. Kinoshitá, H. Furukawa, Toshiharu Yamaguchi, A. Nashimoto, M. Fujii, T. Nakajima, Y. Ohashi. Journal of Clinical Oncology, 2011
1,290 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/de71daf7d6e731a9d26ebc445b973067fa7551d8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Japanese gastric cancer treatment guidelines 2014 (ver. 4) (2016, background): “Various regimens had been tested in numerous clinical trials in Japan without producing solid evidence in support of adjuvant chemotherapy until the efficacy of S-1 was proven in the ACTS-GC trial [29, 30], a study that secured the place of postoperative chemotherapy with S-1 as a standard of care (”
- Gastric cancer: a comprehensive review of current and future treatment strategies (2020, background): “A large-scale study evaluated 206 gastric cancer patients and found that Stage II and III patients had higher survival rates with adjuvant therapy compared to surgery alone (36).”
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, methodology): “The ACTS-GC trial evaluating adjuvant chemotherapy with S-1 following D2 resection in Asian patients demonstrated an OS benefit for patients treated with adjuvant chemotherapy [I, A] [48, 49].”
- Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) (2022, background): “As adjuvant chemotherapy, the efficacy of S-1 was proven in 2006 by the ACTS-GC trial [71, 72], a study that secured the place of postoperative S-1 monotherapy as a standard of care.”
- Japanese gastric cancer treatment guidelines 2018 (5th edition) (2020, background): “Various regimens had been tested in numerous clinical trials in Japan without producing solid evidence in support of adjuvant chemotherapy until the efficacy of S-1 was proven in 2006 by the ACTSGC trial [62, 63], a study that secured the place of postoperative S-1 monotherapy as a standard of care ”